S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
NASDAQ:PETS

PetMed Express Stock Forecast, Price & News

$27.02
-0.32 (-1.17%)
(As of 12/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$27.02
$27.61
50-Day Range
$26.28
$32.00
52-Week Range
$24.75
$57.00
Volume
155,913 shs
Average Volume
607,603 shs
Market Capitalization
$549.83 million
P/E Ratio
21.62
Dividend Yield
4.39%
Beta
0.54
30 days | 90 days | 365 days | Advanced Chart
Receive PETS News and Ratings via Email

Sign-up to receive the latest news and ratings for PetMed Express and its competitors with MarketBeat's FREE daily newsletter.


PetMed Express logo

About PetMed Express

PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail or print advertising campaigns. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug stores & proprietary stores
Sub-Industry
Internet Retail
Current Symbol
NASDAQ:PETS
CUSIP
71638210
Employees
219
Year Founded
1996

Sales & Book Value

Annual Sales
$309.21 million
Cash Flow
$1.62 per share
Book Value
$6.95 per share

Profitability

Net Income
$30.60 million
Pretax Margin
11.50%

Debt

Price-To-Earnings

Miscellaneous

Free Float
19,759,000
Market Cap
$549.83 million
Optionable
Optionable

Company Calendar

Last Earnings
10/24/2021
Ex-Dividend
11/05/2021
Dividend Payable
11/19/2021
Today
12/08/2021
Next Earnings (Estimated)
1/18/2022
Fiscal Year End
3/31/2022

Social Links


MarketRank

Overall MarketRank

2.35 out of 5 stars

Retail/Wholesale Sector

98th out of 276 stocks

Drug Stores & Proprietary Stores Industry

3rd out of 10 stocks

Analyst Opinion: 1.8Community Rank: 3.1Dividend Strength: 3.3Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -












PetMed Express (NASDAQ:PETS) Frequently Asked Questions

Is PetMed Express a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PetMed Express in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PetMed Express stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PETS, but not buy additional shares or sell existing shares.
View analyst ratings for PetMed Express
or view top-rated stocks.

How has PetMed Express' stock price been impacted by COVID-19 (Coronavirus)?

PetMed Express' stock was trading at $25.95 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PETS stock has increased by 4.1% and is now trading at $27.02.
View which stocks have been most impacted by COVID-19
.

When is PetMed Express' next earnings date?

PetMed Express is scheduled to release its next quarterly earnings announcement on Tuesday, January 18th 2022.
View our earnings forecast for PetMed Express
.

How were PetMed Express' earnings last quarter?

PetMed Express, Inc. (NASDAQ:PETS) announced its quarterly earnings data on Sunday, October, 24th. The company reported $0.31 EPS for the quarter, missing analysts' consensus estimates of $0.34 by $0.03. The business had revenue of $67.39 million for the quarter, compared to analyst estimates of $70.90 million. PetMed Express had a net margin of 8.86% and a trailing twelve-month return on equity of 18.44%. During the same quarter in the previous year, the firm earned $0.42 earnings per share.
View PetMed Express' earnings history
.

How often does PetMed Express pay dividends? What is the dividend yield for PetMed Express?

PetMed Express announced a quarterly dividend on Monday, October 25th. Investors of record on Monday, November 8th will be given a dividend of $0.30 per share on Friday, November 19th. This represents a $1.20 annualized dividend and a dividend yield of 4.44%. The ex-dividend date of this dividend is Friday, November 5th.
View PetMed Express' dividend history
.

Is PetMed Express a good dividend stock?

PetMed Express pays an annual dividend of $1.20 per share and currently has a dividend yield of 4.39%. PETS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. PetMed Express has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of PetMed Express is 96.00%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on EPS estimates, PetMed Express will have a dividend payout ratio of 94.49% in the coming year. This indicates that PetMed Express may not be able to sustain their current dividend.
View PetMed Express' dividend history.

What price target have analysts set for PETS?

3 analysts have issued 1 year price targets for PetMed Express' stock. Their forecasts range from $25.00 to $39.00. On average, they anticipate PetMed Express' stock price to reach $30.67 in the next year. This suggests a possible upside of 13.5% from the stock's current price.
View analysts' price targets for PetMed Express
or view top-rated stocks among Wall Street analysts.

Who are PetMed Express' key executives?

PetMed Express' management team includes the following people:
  • Matthew N. Hulett, President, Chief Executive Officer & Director
  • Bruce S. Rosenbloom, Chief Financial Officer & Treasurer (LinkedIn Profile)
  • Alison Berges, Secretary & General Counsel

What is Mendo Akdag's approval rating as PetMed Express' CEO?

5 employees have rated PetMed Express CEO Mendo Akdag on Glassdoor.com. Mendo Akdag has an approval rating of 46% among PetMed Express' employees. This puts Mendo Akdag in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of PetMed Express' key competitors?

What other stocks do shareholders of PetMed Express own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PetMed Express investors own include Intel (INTC), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Alibaba Group (BABA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Verizon Communications (VZ), Netflix (NFLX) and Micron Technology (MU).

What is PetMed Express' stock symbol?

PetMed Express trades on the NASDAQ under the ticker symbol "PETS."

Who are PetMed Express' major shareholders?

PetMed Express' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.16%), Renaissance Technologies LLC (4.03%), Penserra Capital Management LLC (2.99%), Dimensional Fund Advisors LP (2.80%), Allianz Asset Management GmbH (1.87%) and Bank of New York Mellon Corp (1.83%). Company insiders that own PetMed Express stock include Bruce S Rosenbloom, Gian Fulgoni, Menderes Akdag and Ronald J Korn.
View institutional ownership trends for PetMed Express
.

Which institutional investors are selling PetMed Express stock?

PETS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Penserra Capital Management LLC, Jane Street Group LLC, Profit Investment Management LLC, Renaissance Technologies LLC, BlackRock Inc., PEAK6 Investments LLC, and Voloridge Investment Management LLC. Company insiders that have sold PetMed Express company stock in the last year include Bruce S Rosenbloom, Gian Fulgoni, Menderes Akdag, and Ronald J Korn.
View insider buying and selling activity for PetMed Express
or view top insider-selling stocks.

Which institutional investors are buying PetMed Express stock?

PETS stock was purchased by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Hotchkis & Wiley Capital Management LLC, Point72 Asset Management L.P., Nierenberg Investment Management Company Inc., Richard P Slaughter Associates Inc, Aviva PLC, Man Group plc, and Pacer Advisors Inc..
View insider buying and selling activity for PetMed Express
or or view top insider-buying stocks.

How do I buy shares of PetMed Express?

Shares of PETS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PetMed Express' stock price today?

One share of PETS stock can currently be purchased for approximately $27.02.

How much money does PetMed Express make?

PetMed Express has a market capitalization of $549.83 million and generates $309.21 million in revenue each year. The company earns $30.60 million in net income (profit) each year or $1.25 on an earnings per share basis.

How many employees does PetMed Express have?

PetMed Express employs 219 workers across the globe.

When was PetMed Express founded?

PetMed Express was founded in 1996.

What is PetMed Express' official website?

The official website for PetMed Express is www.1800petmeds.com.

Where are PetMed Express' headquarters?

PetMed Express is headquartered at 420 SOUTH CONGRESS AVENUE, DELRAY BEACH FL, 33445.

How can I contact PetMed Express?

PetMed Express' mailing address is 420 SOUTH CONGRESS AVENUE, DELRAY BEACH FL, 33445. The company can be reached via phone at (561) 526-4444 or via fax at 561-526-4445.


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.